Growth hormone-releasing hormone (GHRH) peptides such as sermorelin sit at the center of a long-running research question: as the somatotropic axis quiets with age, can restoring pulsatile growth hormone and insulin-like growth factor-1 (IGF-1) signaling meaningfully influence brain aging? This article surveys what the primary literature actually reports, and where the evidence stops.

What sermorelin is and how it engages the somatotropic axis

Sermorelin corresponds to the first 29 amino acids of human growth hormone-releasing hormone, GHRH(1-29). This fragment is the shortest sequence that retains the full biological activity of the native 44-residue hormone, which is why it became a standard research tool for probing pituitary function.⁵ When it binds the GHRH receptor on somatotroph cells of the anterior pituitary, it triggers synthesis and release of endogenous growth hormone (GH). Because sermorelin acts one step upstream of the pituitary, GH is released in the body's own pulsatile rhythm rather than as a continuous, exogenously imposed level.⁵

Growth hormone released in this way circulates to the liver and peripheral tissues, where it stimulates production of insulin-like growth factor-1 (IGF-1). The GHRH → GH → IGF-1 cascade is collectively described as the somatotropic axis, and it is this axis — not sermorelin acting directly on neurons — that connects the peptide to any downstream discussion of brain biology. In controlled work with older men, subcutaneous GHRH(1-29) given twice daily raised both 24-hour GH output and IGF-1 back toward levels seen in younger men, confirming that the aged pituitary remains responsive to GHRH stimulation.⁴

Qovigen catalogues sermorelin in 5 mg and 10 mg research vials. Related GHRH-family peptides used in the cognition literature, most notably tesamorelin, are discussed below because they — not sermorelin — underpin the strongest human data.

Why the GH/IGF-1 axis declines with age — and how that maps onto cognition

Secretion across the somatotropic axis falls progressively from early adulthood, a phenomenon sometimes termed the “somatopause.” Peak GH pulse duration and circulating IGF-1 are measurably lower in older than in younger men, and this decline runs in parallel with age-related shifts in body composition and physical function.⁴ Reviews of the aging GH/IGF-1 axis note that the same decline correlates cross-sectionally with cognitive performance, positioning reduced IGF-1 as one candidate contributor among many to age-related cognitive change rather than as a proven cause.⁷

The interest for neurodegeneration researchers is that IGF-1 is highly expressed within the brain and is essential for normal neural development. It exerts anti-apoptotic actions, promotes projection-neuron growth, dendritic arborization and synaptogenesis, and supports vascular function in the central nervous system.⁷ When these trophic inputs diminish, several age-associated processes are thought to become less well buffered:

• Reduced neurogenic and synaptic support. Lower GH/IGF-1 signaling is associated in animal models with diminished hippocampal progenitor proliferation and blunted plasticity.⁶
• Excitotoxic and oxidative vulnerability. IGF-1 opposes glutamate-mediated excitotoxic signaling in preclinical systems; when it is scarce, neurons may tolerate metabolic and oxidative stress less well.⁹
• Overlap with Alzheimer-type pathology. Because GHRH, GH and IGF-1 all influence brain function and decline with age, the axis has been proposed as one node relevant to Alzheimer disease pathogenesis, though it is not established as a driver.⁸

It is important to keep the direction of evidence clear here: these are associations and mechanistic hypotheses. They motivate the experiments described in the next sections; they do not by themselves demonstrate that raising the axis with a GHRH peptide alters the course of any human neurodegenerative disease.

Mechanism: GH and IGF-1 signaling inside the brain

The proposed route by which a GHRH peptide could touch cognition is indirect and multi-step. Sermorelin (or another GHRH analogue) stimulates pituitary GH; GH raises IGF-1 both peripherally and, to some degree, within the brain; and IGF-1 then engages its receptor on neurons, glia and cerebral vasculature. In experimental work, this signaling has been linked to three broad categories of effect.⁶

Neuronal survival and myelin support

IGF-1 acts as a neurotrophic factor that promotes neuron survival and influences oligodendrocyte biology and myelination. In rodent models, both IGF-1 and GH therapy have been reported to induce cell genesis in the adult brain, with IGF-1 increasing progenitor proliferation and the number of new neurons, oligodendrocytes and blood vessels in the dentate gyrus of the hippocampus.⁶

Plasticity and neurogenesis

Because the hippocampus is central to learning and memory encoding, IGF-1-associated increases in hippocampal neurogenesis and synaptic plasticity are the mechanistic hook most often invoked for cognition. The authors of this literature are explicit that clinical translation is not yet warranted: further work in animal models of brain injury is required before trials can be justified on that mechanistic basis alone.⁶

Neurochemical modulation

A human imaging substudy adds a distinct layer of mechanism. Using proton magnetic resonance spectroscopy, 20 weeks of GHRH-analogue administration was associated with increased brain levels of the inhibitory neurotransmitter GABA across several regions, increased N-acetylaspartylglutamate in frontal cortex, and decreased myo-inositol in the posterior cingulate — the last being an osmolyte linked to Alzheimer pathology.³ Treatment-related IGF-1 change correlated with the GABA change in the posterior cingulate, offering a candidate — but not confirmed — neurochemical explanation for the cognitive signals seen in the parent trial.³

What the human GHRH cognition trials actually tested

Three primary reports form the backbone of the human GHRH-and-cognition literature, and reading them precisely matters, because they are frequently miscited.

The earliest, a controlled trial in 89 healthy older adults, examined six months of daily GHRH versus placebo and reported improved performance on several measures, including Wechsler Adult Intelligence Scale-Revised performance IQ and picture arrangement, independent of sex or baseline cognitive capacity.¹ The two later trials came from the University of Washington group and used tesamorelin, a stabilized GHRH analogue, at 1 mg/day for 20 weeks. The larger randomized, double-blind, placebo-controlled trial enrolled 152 adults — including 66 with mild cognitive impairment — and reported a favorable effect on cognition overall, driven by executive function, alongside a 117% increase in IGF-1 that stayed within the physiological range.² A magnetic resonance spectroscopy substudy of 30 participants provided the neurochemical findings described above and replicated the cognitive effect in that smaller sample.³

Two honest caveats accompany this table. First, the strongest results used tesamorelin, not sermorelin; the two are related GHRH analogues but are not identical molecules, and extrapolating one to the other is an assumption rather than a demonstrated equivalence. Second, adverse events in the 20-week trial were reported by roughly two-thirds of treated participants, albeit rated as mild, and the investigators explicitly called for longer trials to gauge any durable relevance to brain health.² These are early-phase, hypothesis-generating findings, not a settled clinical picture.

Preclinical evidence for IGF-1 neuroprotection

Because the human dataset is small, much of the biological rationale rests on animal and cell models of IGF-1 itself. A body of work reviewed in recent literature indicates that IGF-1 and its receptors are widely expressed in the central nervous system and that IGF-1 can induce neuroprotective effects against glutamate-mediated excitotoxic signaling — a pathway common to ischemic stroke, brain trauma, epilepsy and Alzheimer disease models.⁹ In rodent studies, delivering IGF-1 by various routes rescued pathophysiological and behavioral abnormalities, and several clinical studies reported acceptable tolerability, though efficacy for neurological endpoints remains unproven.⁹

Developmental models add mechanistic detail. In a neonatal mouse model of systemic hypoxia, growth hormone treatment restored the disrupted GH/IGF-1 axis and upregulated neuroprotective, hypoxia-inducible growth factors in the developing brain, reducing apoptotic cell death.¹⁰ While that model concerns perinatal injury rather than age-related neurodegeneration, it illustrates the same theme running through the field: manipulating the axis changes brain growth-factor expression and cell-survival readouts in controlled experimental systems.¹⁰ Whether those readouts translate into disease-modifying outcomes in aging humans is exactly the gap the small GHRH trials began, but did not close, to probe.

Sermorelin, tesamorelin and exogenous growth hormone are not interchangeable

Discussions of “GH therapy” often collapse three distinct research tools that behave differently.

Sermorelin is GHRH(1-29), the minimal active fragment; it drives pituitary GH release in the body's native pulsatile pattern and is subject to normal feedback regulation.⁵ Tesamorelin is a stabilized GHRH analogue engineered for greater metabolic stability, and it is the molecule used in the 20-week cognition trials.² Recombinant human growth hormone bypasses the pituitary entirely, imposing GH at levels set externally rather than by physiological rhythm. Reviews of the aging axis contrast GHRH-based stimulation, which preserves pulsatility and feedback, with direct GH administration, which does not.⁶

This distinction matters for interpreting the literature. When a study reports a cognitive signal from tesamorelin, that is a statement about a specific stabilized GHRH analogue in a specific 20-week protocol; it is not automatically a statement about sermorelin, and still less about GH supplementation in general. Researchers comparing these peptides — sermorelin, tesamorelin, or GH secretagogues such as those in Qovigen's GROW-H blend — should treat each as a separate variable rather than assuming class-wide equivalence.

Limits, open questions and regulatory status

Several limits deserve to be stated plainly. The human cognition trials are small, short (20–26 weeks), and concentrated in one research group; effect sizes were modest and centered on executive-function composites rather than global cognition. No published randomized trial has tested sermorelin specifically against a cognitive or neurodegeneration endpoint. The mechanistic literature, while substantial, is dominated by rodent and in-vitro models whose translation to human aging is uncertain.⁶⁹ Reviews that raise the GH/IGF-1 axis as relevant to Alzheimer disease are careful to frame it as a target for investigation, not an established intervention.⁸

On regulation: no GHRH peptide is approved by the FDA for cognitive decline, dementia or neurodegeneration. Tesamorelin is approved in the United States for a distinct, unrelated indication (HIV-associated lipodystrophy), and its cognition data remain investigational. Sermorelin is not currently marketed as an approved drug in the United States. Accordingly, Qovigen supplies sermorelin strictly as a research-use-only reference material for qualified laboratory investigation, not for human administration. The open questions — adequately powered trials, longer follow-up, head-to-head comparison of GHRH analogues, and biomarker-anchored endpoints — are the reason this remains an area of active research rather than settled practice.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.